This event is made possible by:

This event is financed by:

This event is endorsed by:

About Assobiotec

Assobiotec, the Italian Association for the Development of Biotechnology Assobiotec, the Italian Association for the Development of Biotechnology, represents approximately 130 businesses and science and technology parks operating in Italy across the various fields that use biotechnology: healthcare, agriculture, the environment, and industrial processes. The Association brings together a variety of enterprises and organisations, of different sizes and from different spheres of operation, all of which are strongly united by a propensity for innovation and by their use of biotechnology – a strategic stimulus for development in every industrial field, offering concrete responses to increasingly pressing needs in terms of public health, environmental conservation, food and agriculture.

Established in 1986 as a part of Federchimica, Assobiotec is also a part of Confindustria and a founding member of EuropaBio, the European Association for Bioindustries, and of the ICBA, the International Council of Biotechnology Associations. In Italy, through Federchimica, it is a founding member of ALISEI (the Italian National Cluster of Life Sciences) and of SPRING (the Italian National Cluster of Green Chemistry). It is an ongoing and active participant in the work of the Blue Growth cluster and of CLAN (the Italian National AgriFood Cluster)

About BIO Deutschland

BIO Deutschland and our COVID-19 efforts

BIO Deutschland is the sector organization of the German biotechnology industry. The association has the objective to support and promote the development of an innovative economic sector based on modern biosciences. BIO Deutschland is based in Berlin and currently has over 340 members.

BIO Deutschland is in close contact with federal agencies to support the actions of the government and to communicate the needs of German biotech companies in this crisis. A comprehensive list of BIO Deutschlands members who actively engage in the fight against COVID-19 can be found here

About BioM

BioM is the central network organization for the biotechnology sector in Munich and Bavaria, commissioned by the Bavarian Ministry of Economic Affairs. As a non-profit organization, BioM supports the biotech community with its extensive network in a variety of ways. The cluster management acts as a centralized access point to connect Bavarian life science companies with relevant national and international partners.

BioM supports Bavarian biotech companies at every stage of setting up their business with its unique support program “inQlab”, tailor-made for aspiring start-ups and entrepreneurs in the life sciences sector. In addition, BioM offers a variety of workshops and training courses as well as current news, event information, a company database and a job exchange. Discover more under:

In the context of the COVID-19 pandemic, it is of the utmost importance to accelerate the discovery and development of safe and more effective drugs, vaccines and diagnostics. This is why BioM started a call for solutions against COVID-19 and the BioM-COVID-19 exchange platform to find the right partners or to help with funding.

About BioRN

BioRN is the science and industry cluster of the Rhine-Main-Neckar region around Heidelberg, one of Germany’s strongest biotech hubs. It is a non-profit network fostering health innovations and serving its members by creating a rich translational ecosystem as well as promoting, representing and connecting the regional innovation stakeholders.

Our vision is to develop the region into a world-leading life science cluster attracting international investments and top global talent.

BioRN has more than 100 institutional members, including the top academic and research institutions, 7 global pharmaceutical companies, a large range of small and medium-sized enterprises bolstering the life science ecosystem as well as local government organizations and interest groups.

About BioWin

BioWin was created in July 2006 and today is the key reference in the field of health biotechnology and medical technologies in Wallonia (a region located south of Brussels, Belgium). The cluster brings together Walloon players who are involved, at every stage, in the research, development and production of innovative products and services: academic and clinical research laboratories, accredited research centres, large industrial groups, small and medium-sized enterprises (SMEs), service providers, engineering colleges and universities, business incubators, investors, policy makers and associated bodies.
More information :

Regarding the crisis we are currently facing, the cluster set up a Cooperation Platform COVID-19 to gather health initiatives around specific and important themes. Join this platform if you have offers/requests which can help solve the pandemic:

About DrugBank

DrugBank is the world’s largest knowledge base of structured pharmaceutical data, enabling data-driven decision-making in the healthcare, pharmaceutical, and medical spaces. By using DrugBank, companies and researchers can more efficiently discover or repurpose new drugs, and improve treatments for patients. The core of DrugBank’s knowledge base consists of proprietary authored content describing the clinical level information about drugs such as side effects, drug interactions, as well as molecular level data such as chemical structures, metabolism, and what proteins a drug interacts with.

Since the COVID-19 crisis began DrugBank has been cited in over fifty-five research papers looking at novel therapies for COVID-19, and has seen an increase of over 6000% in individuals searching terms on related to novel candidates for the virus. The number of monthly requests from academic groups requesting to use DrugBank for research has skyrocketed from 250 per week to more than 500 per week, and DrugBank is also being used as a core resource for dozens of research platforms around the globe, including the recently launched COVID-19 ‘Deep Search’ Knowledge Graph from IBM.

As an evidence-based pharmaceutical technology company, DrugBank is keen to assist in finding a treatment for the virus, and has released a research white paper summarizing the current status of drug repurposing being completed by companies around the world. They are also in the final stages of releasing a COVID-19 Information Dashboard, to provide a comprehensive summary of relevant research in an effort to help researchers find the information they need quickly and effectively.


EFPIA and relevant Covid-19 activities

EFPIA is the voice of the research-based pharmaceutical industry in Europe. As long as this public health crisis will be ongoing, #WeWontRest in fighting the COVID-19 pandemic.

As an industry, we are committed to working collaboratively across the research and healthcare communities, utilising our world-leading science, people and resources to tackle this outbreak. EFPIA members committed to do everything in their power to ensure safe supply of medicines to the patients that need them; to carry R&D into novel vaccines, medicines and diagnostics to fight against COVID-19; and to provide governments and healthcare systems with the necessary support on the ground.     

To effectively fight against healthcare challenges, members of EFPIA continually evolve the research paradigms and expand the pre-competitive space to accelerate the development of new health solutions. Through the Innovative Medicines Initiative, the largest public private partnership on health research worldwide, EFPIA members will join forces and engage with academia to develop new diagnostics and treatments to address the current and future outbreaks of COVID-19. IMI received 144 proposals in response to its fast track call 21 specifically dedicated to COVID-19, many of which involving a number of EFPIA members and Partners in Research; the final selection of projects which will be funded by IMI will be known in early May.

Visit the EFPIA webpage to explore few of many examples of how EFPIA member companies are supporting efforts in the detection, prevention and treatment of the COVID-19 outbreak. Visit the IMI website for more information about Fast Track call 21 on COVID-19.

Visit the EFPIA webpage to explore few of many examples of how EFPIA member companies are supporting efforts in the detection, prevention and treatment of the COVID-19 outbreak. Visit the IMI website for more information about Fast Track call 21 on COVID-19.


EUCOPE is Europe’s trade body for small to medium-sized innovative companies working in the field of pharmaceuticals and medical technologies.

Based in Brussels, Belgium, EUCOPE gives voice to more than 900 research-oriented innovative companies and associations active in research, development of pharmaceuticals, biotechnologies and medical devices. Many of our members are developing therapeutic solutions for persons living with a rare disease, who had little to no treatment available just a few years ago.

Involved in multiple expert groups of the European Commission and the EMA, EUCOPE is contributing to important EU and national legislative dossiers. EUCOPE’s relationship with the European Parliament and the Member States supports our members’ activities at the national level and helps to bring innovative therapies and medical technologies to patients all over Europe.

About is a dynamic, member driven organisation with currently more than 340 members from Belgium and abroad. We help our members to create value by organising networking and training activities, supporting internationalisation, providing services and building expertise. and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

Our mission is to create value for our members through an appropriate focus in our actions and to act as a respected source of information for key stakeholders/media and a voice to the local governments.

Discover what we’re all about on


Established in October 1945 with the name of Chosun Pharmaceutical Manufacturers Association at first, the KPBMA now has 198 pharmaceutical companies as its members in Korea. The KPBMA is the largest pharmaceutical industry organization in Korea, with a membership that includes 179 domestic pharmaceutical firms and 19 multinational corporations. To achieve its goal of ‘improving national healthcare through the sound development of the pharmaceutical industry,’ the KPBMA plays a variety of roles such as policy-supporting activities, educations, and supporting to member companies in Korea. Joining the IFPMA as a regular member since 1978, the KPBMA has also been making cooperation actively with global players. In an effort to fight COVID-19, the Korean government did its best and now Korea is one of the best countries showing the success of containment of COVID-19 spread. Now, many KPBMA member companies are doing their best to develop drugs and vaccines including BUKWANG Pharmaceutical, Eutilex, ImmuneMed, Cellivery, NOVACELL TECHNOLOGY, G FLAS LIFE SCIENCES, GC Pharma and SK bioscience.

About LMI

The Association of the Pharmaceutical Industry in Norway – LMI represent large, medium, small and start-up biopharmaceutical companies. With a member base of 59 companies, the association works to ensure optimal conditions for the entire value chain from drug development to market access, distribution and patient information.

Our mission is to save lives every single day, and create knowledgebased jobs for the future. We are constantly working on increasing awareness of industry contributions to society, connecting excellent academic research environments to industry projects and creating favourable market conditions for the industry.

About Life Sciences Queensland

Life Sciences Queensland Limited (LSQ) creates an opportunity for industry stakeholders to come together and cooperate to grow their businesses and help create a dynamic, internationally competitive and sustainable life sciences industry in Queensland, Australia. LSQ is helping to shape the strategic direction of the industry in the State and influence public policy. We also provide members with tools, services, market intelligence and access to an international network of life sciences organisations with the aim of identifying new business opportunities and accelerating business growth.

In a broader sense, LSQ is working to enhance Queensland’s national and international reputation as a centre of commercial and research excellence in life sciences. LSQ is an industry-led vehicle, which promotes and supports all segments of the Queensland life sciences industry.

LSQ engages the full spectrum of the Queensland life sciences industry, to assist the growth of individual organisations and industry segments, and to build the profile, capacity and capability of the sector to help ensure long term economic, social and environmental benefits to Queensland and its members. The primary objectives of LSQ are to:

  • Develop the industry by supporting local industry forums and providing members with tools to accelerate their business growth.
  • Create new business opportunities for members through market outreach (e.g. business development services, event management, a co-ordinated approach to international business meetings) that members cannot readily or cost-effectively achieve on their own.
  • Play a leading role in influencing public policy so as to help ensure sustainable growth of the Queensland Life Science Industry.

About MassBio

MassBio’s mission is to advance Massachusetts’ leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. MassBio represents the premier global life sciences and healthcare hub, with 1,300+ members dedicated to preventing, treating, and curing diseases through transformative science and technology that brings value and hope to patients. Founded in 1985, MassBio works to advance policy and promote education, while providing member programs, events, industry information, and services. For more information, visit

About One Nucleus

One Nucleus: The Cambridge - London Life Science Membership Organisation

We support Europe’s largest Life Science cluster encompassing the London-Cambridge-East of England region via knowledge transfer, connectivity, inward investment and growth.

This support helps members achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.

Find out more here:

About Polepharma


As French leading exporter of drugs, Polepharma is the first pharmaceutical alliance in Europe. Its network relies on a team of expertswho aim at stimulating industrial and economic development of the pharmaceutical and biopharmaceutical industry with actions that promote competitiveness, innovation, attractiveness and the “Made in France”. Polepharma’s members represent pharmaceutical laboratories, suppliers, manufacturers, public and private institutions, universities, training and research centers.

Key figures

1st pharmaceutical alliance in Europe (ensures 53% of drug production in France)
3 regions : Centre-Val de Loire, Normandie and Ile de France
4 branches located in Chartres, Louviers, Tours et Paris.
Annual export turnover of 25,3 billion euros
300 member companies from the health sector
60 000 jobs which embrace the different actors of the health sector.

LinkedIn - Twitter